{"product_id":"ipilimumab-elisa-kit-db651018","title":"Ipilimumab ELISA Kit - DB651018","description":"\u003cp\u003eIpilimumab ELISA Kit\u003c\/p\u003e\n\n\u003cp\u003eSize: 96T\u003c\/p\u003e\n\n\u003cp\u003eCatalogue Number: DB651018-96\u003c\/p\u003e\n\n\u003cp\u003eCitations, Manuals and MSDS Available upon request.\u003c\/p\u003e\n\n\u003cp\u003eStability and Storage: The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.\u003c\/p\u003e\n\n\u003cp\u003eDetection Method: Colorimetric\u003c\/p\u003e\n\n\u003cp\u003eSample Type: Plasma, Serum\u003c\/p\u003e\n\n\u003cp\u003eAssay Type: Quantitative\u003c\/p\u003e\n\n\u003cp\u003eSensitivity: 0.156 μg\/ml\u003c\/p\u003e\n\n\u003cp\u003eRange: 0.31-5 μg\/mL\u003c\/p\u003e\n\n\u003cp\u003eRecovery: 80-120%\u003c\/p\u003e\n\n\u003cp\u003eBackground: Ipilimumab is a fully human IgG1 kappa antibody that binds to CTLA-4 (cytotoxic T lymphocyte associated antigen 4), a molecule on T cells that is indicated for unresectable or metastatic melanoma. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells. The proposed mechanism of action is indirect, and may be through T-cell - mediated anti-tumor immune responses.\u003c\/p\u003e\n\n\u003cp\u003eShipping: 2-8 ℃\u003c\/p\u003e\n\n\u003cp\u003eFor Research Use Only.\u003c\/p\u003e","brand":"abinScience","offers":[{"title":"Default Title","offer_id":45353677586611,"sku":"DB651018-96","price":1576.4,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0305\/9482\/6376\/files\/abinscience.png?v=1773676488","url":"https:\/\/afsbio.com\/products\/ipilimumab-elisa-kit-db651018","provider":"AFSBio Inc.","version":"1.0","type":"link"}